IQVIA Holdings Inc. (IQV) exhibits 45.0% gross margins and 9.4% return on invested capital within Health Care (Biotechnology: Commercial Physical & Biological Resarch), balanced against a 20.4x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 13.4% operating margin and 9.4% ROIC, outpacing sector cost of capital.
ROIC: 9.4% // GM: 45.0%YoY revenue trajectory of +5.9% paired with 4.24% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.9% // FCF YLD: 4.24%Altman Z-Score of 2.22 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.22 // F-SCORE: 6/9Trading at 33.3x trailing P/E (31.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 33.3x // EV/EBITDA: 20.4xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $267.33 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Commercial Physical & Biological Resarch require continuous execution to defend 8.3% net margins.
NET MARGIN: 8.3% // D/E: 2.14x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for IQV & activate live FRED threshold breach alerts.